Ping An CSI HK Equities Medical and Health Integration ETF

Sontek, China Pharmaceutical, and Huidai Acquisition-Z Disclose Latest Shareholder Rights

Chinese Innovative Pharmaceutical Companies Discuss Overseas Strategies: From 'Riding Others' Ships' to 'Building Their Own Ships'

Chairman Cai Dongchen of Stone Pharmaceutical Group Increased Shareholding to 25.26%

China's Pharmaceutical Industry Transforms into a Global Innovation Hub

Jade Pharmaceutical's SYH2085 Approved for Clinical Trials in China

JD Health Launches Billion-Yuan Brand Alliance for Digital Upgrade of Corporate Health Consumption Market

WuXi Biologics Receives CDP Climate Change and Water Security 'A' Rating

JPMorgan Sees Opportunities in China's Healthcare Sector, Recommends Biotech and CXO Stocks

Sukoddju Injection Phase III Clinical Trial Achieves Positive Results for Severe Plaque Psoriasis Treatment

Morgan Stanley Downgrades JP Group’s Target Price and Adjusts Profit Projections

Glenmark Pharmaceuticals Ltd Secures Exclusive Rights to Aumolertinib from Hansoh Pharmaceutical

Hansoh Pharmaceutical's Wholly-owned Subsidiary Enters into Exclusive Licensing, Collaboration and Distribution Agreement for Amivantamab with Glenmark

Cancer Biologics Kangdein Biotech Makes Multiple Progresses in Core Product Pipeline

Innovent Biologics' Masdutide Receives Approval from Macau's Drug Regulatory Authority

Morgan Stanley Raises Target Price for AliHuang to HKD 4.6

JD Health Announces New Progress in Tumor Prevention and Treatment with Medical Large Models

Shire Pharmaceutical Group's Liposomal Irinotecan Injection Approved for New Indication

UBS Analyst Maintains Buy Rating on Hansoh Pharmaceutical

Macquarie Analyst Maintains Buy Rating on BeiGene

Stone Pharmaceutical's Liposomal Irinotecan Injection Approved for First-Line Pancreatic Cancer Treatment

02007

01093

<p>The Hang Seng index fell sharply, retreating to H$20,000, down over 11% from its year-to-date high. This decline is attributed to China's modest growth forecast and the Federal Reserve's hawkish stance on interest rates. All stocks in the index dropped, with CSPC Pharma and Country Garden Services among the worst performers. The index is expected to continue its bearish trend, potentially falling to H$18,670.</p>

- The Hang Seng index dropped significantly, retreating to H$20,000 amid a global equity downturn, marking an 11% decline from its yearly high.  
- Factors influencing this decline include a modest 5% growth forecast for China’s economy and statements from Federal Reserve Chair Jerome Powell regarding continued aggressive interest rate hikes.  
- Analysts now predict a potential increase of 0.50% in rates, which could reach 6%, impacting Hong Kong's financial market and leading to a likely further decline of the Hang Seng index towards H$18,670.

Invezz

COUNTRY GARDEN

CSPC PHARMA

Hang Seng index enters a period of stable disequilibrium

00241

06618

<p>The Hang Seng index fell over 3% to H$18,562, its lowest since June 1, due to concerns about the Chinese economy and Federal Reserve rate hikes. All index constituents were in the red, with JD Health and Alibaba Health leading the decline. The index is expected to continue falling unless it rises above the key resistance point at $18,795.</p>

- The Hang Seng index fell over 3% to H$18,562 amid ongoing concerns about the Chinese economy and Federal Reserve policies.  
- The index's decline was influenced by slower-than-expected recovery in China's manufacturing and services sectors, and the belief that the U.S. requires gradual interest rate hikes.  
- Notable declines were observed in major stocks such as JD Health and Alibaba Health, with continued pressure anticipated unless the index rises above H$18,795.

ALI HEALTH

JD HEALTH

All Hang Seng index constituents dive as China growth concerns linger